Why refractory epilepsy in dogs is getting renewed attention

Veterinary Practice News on June 1, 2026, published an Education Center article by neurologist Simon R. Platt spotlighting refractory, or drug-resistant, epilepsy in dogs, a condition in which seizures continue despite at least two appropriately chosen anti-seizure drugs used at correct doses. The piece, sponsored by PRN Pharmacal, argues that veterinary teams should aim for seizure freedom rather than settling for partial improvement, and it underscores that roughly 30% of dogs with idiopathic epilepsy may prove treatment-resistant. The article also points to breed effects, early seizure frequency, drug tolerance, and the need for both pharmaceutical and non-pharmaceutical strategies as key parts of case management. (veterinarypracticenews.com)

Why it matters: For veterinary professionals, the article is a reminder that “breakthrough” seizures aren’t just a medication-adjustment problem. Refractory cases often require repeated therapeutic drug monitoring, careful review of adherence and dosing intervals, seizure logs, and a broader workup to confirm idiopathic epilepsy versus structural, metabolic, toxic, or reactive causes. Outside the sponsored article, current clinical context supports that these cases are common enough to shape everyday practice: Cornell notes that about 20% of dogs need more than one anti-seizure medication, while other veterinary neurology commentary puts refractory epilepsy closer to one in three dogs. Adjunctive tools such as levetiracetam pulse therapy for cluster-prone patients, rescue benzodiazepines, and medium-chain triglyceride dietary strategies are increasingly part of the conversation. (vet.cornell.edu)

What to watch: Expect continued attention on combination protocols, diet-based adjuncts, and newly validated labeled therapies after PRN Pharmacal’s potassium bromide product KBroVet gained full FDA approval in February 2026 for control of seizures associated with idiopathic epilepsy in dogs. (prnewswire.com)